|
|
|
|
||
Buy
Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B SubjectsNovember 16, 2020 Data released today expands on November 15, 2020 AASLD presentation Repeat dosing of 60 mg AB-729 every 4 weeks resulted in robust and continuous mean declines in HBsAg decline at week 20 (-1.71 log10IU/mL, N=7) and further reductions continued beyond week 20 (-1.84 log10 IU/mL, N=3) In HBV DNA positive subjects, a single 90 mg AB-729 dose resulted in robust mean declines in HBsAg (-1.02 log10 IU/mL), HBV DNA (-1.53 log10 IU/mL), HBV RNA and HBcrAg at week 12 Results support advancement into Phase 2 combination clinical trials with AB-729 dosing as infrequently as every 8 or 12 weeks Conference Call and Webcast Scheduled Today at 8:00 am ET |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
34960 | Re: Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects | Patc | 0 | 11/17/2020 8:11:16 AM |